Effects of Ulcerative Colitis Treatments on Heart Health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how treatments for ulcerative colitis, specifically anti-TNF agents, vedolizumab, and tofacitinib, affect cardiovascular risk factors such as aortic stiffness and carotid intima-media thickness. It aims to measure these cardiovascular indicators at baseline and after 3 and 12 months of treatment. By comparing these metrics, the study seeks to understand the potential cardiovascular benefits or risks associated with these medications in patients with ulcerative colitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ulcerative colitis evolving for at least 6 months,
* Patient older than 18 years,
* Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or tofacitinib,
* Written informed consent.

Exclusion Criteria:

* Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable dosage within the 3 months before the study and over the study period,
* Patients with a cardiovascular event such as myocardial infarction and stroke,
* Diabetic patient,
* Pregnant women,
* Minor
* people unable to give their consent to participate

Where it's running

• CHU Amiens
  Amiens, France Recruiting

Study contacts

• Study coordinator: Mathurin Fumery, Pr
• Email: Fumery.mathurin@chu-amiens.fr
• Phone: 03 22 08 88 51

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing subcutaneous and intravenous vedolizumab for inflammatory bowel disease with remote monitoring

  This study is testing if a digital health system can help people with inflammatory bowel disease stick to their vedolizumab treatment, whether they receive it through an injection under the skin or through an IV, and how it affects their health over 22 weeks.

  Recruiting at 2 sites Mercy Medical Center · New Orleans, Louisiana and 5 other locations · NCT06750731

• Combining Probiotic VSL#3 with Vedolizumab for Moderate Ulcerative Colitis

  This study is testing if adding a probiotic called VSL#3 to the medication Vedolizumab can help adults with moderate ulcerative colitis feel better.

  Recruiting at 3 sites Phase 4 Second Affiliated Hospital, Zhejiang University, School of Medicine · Beijing, Beijing Municipality and 11 other locations · NCT06609447

• Treatment of Ulcerative Colitis and Crohn's Disease with Vedolizumab

  This study is testing if a new medication called Vedolizumab can help adults with Ulcerative Colitis or Crohn's Disease feel better and stay symptom-free over a year.

  Recruiting at 78 sites Phase 4 Takeda · Birmingham, Alabama and 100 other locations · NCT06581328

• Long-term vedolizumab treatment for children and teenagers with ulcerative colitis or Crohn's disease

  This extension tests whether continuing subcutaneous vedolizumab is safe and helps children and teenagers with moderate to severe ulcerative colitis or Crohn's disease stay well.

  Recruiting at 12 sites Phase 3 Takeda · Phoenix, Arizona and 46 other locations · NCT06405087

• Vedolizumab treatment for children and teenagers with ulcerative colitis or Crohn's disease

  This study is testing how well the drug vedolizumab works for children and teenagers with ulcerative colitis or Crohn's disease when given through injections after an initial dose through an IV.

  Recruiting at 26 sites Phase 3 Takeda · Phoenix, Arizona and 53 other locations · NCT06100289

• Vedolizumab effects on gut microbes and symptom improvement in ulcerative colitis

  This study will test whether vedolizumab changes gut microbes and metabolites and helps adults with moderate to severe ulcerative colitis.

  Recruiting Phase 4 Second Affiliated Hospital, Zhejiang University, School of Medicine · Zhengzhou, Hangzhou · NCT05481619

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.